9th Update on Fabry Disease
Idorsia Posters
Idorsia will present the following two posters at the 9th Update on Fabry Disease 2026:
Poster 1: Lucerastat effect on kidney function in patients with Fabry disease: 4-Year results from the ongoing Open-Label Extension (OLE) of the Phase 3 clinical program
Poster 2: Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY Open-Label Extension study
WORLDSymposium™
Idorsia posters
Idorsia presented the following two posters at WORLDSymposium™ 2026:
Additional information
On January 10, 2026, the results from the pivotal
Phase 3 MODIFY study and its open-label extension evaluating lucerastat, an oral substrate reduction therapy, in adults with Fabry disease were published in Nature Communications.